Fiche publication
Date publication
octobre 2020
Journal
Bioorganic & medicinal chemistry letters
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DESAUBRY Laurent
,
Dr NEBIGIL-DESAUBRY Canan
Tous les auteurs :
Wang D, Tabti R, Elderwish S, Djehal A, Chouha N, Pinot F, Yu P, Nebigil CG, Désaubry L
Lien Pubmed
Résumé
The stomatin/prohibitin/flotillin/HflK/HflC (SPFH) domain is present in an evolutionarily conserved family of proteins that regulate a myriad of signaling pathways in archaea, bacteria and eukaryotes. The most studied SPFH proteins, prohibitins, have already been targeted by different families of small molecules to induce anticancer, cardioprotective, anti-inflammatory, antiviral, and antiosteoporotic activities. Ligands of other SPFH proteins have also been identified and shown to act as anesthetics, anti-allodynia, anticancer, and anti-inflammatory agents. These findings indicate that modulators of human or bacterial SPFH proteins can be developed to treat a wide variety of human disorders.
Mots clés
Allodynia, Anesthesia, Cancer, Drug discovery, Infectious diseases, Lipid rafts, Scaffold proteins
Référence
Bioorg Med Chem Lett. 2020 Oct 6;:127600
